Clinical trials: Severe Psoriasis
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Moderate to Severe Plaque Psoriasis
A Phase 2 Clinical Study of KHK4827
This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT01748539
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00504270
- Testing
- RG3421 120mg, RG3421 20mg
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and…
- Trial name
- NCT02156466
- Testing
- MSB0010841
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plaque Psoriasis
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07251998
- Testing
- ICP-332 Tablets
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from…
- Trial name
- NCT04102007
- Testing
- Risankizumab
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 244 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
- Trial name
- POETYK-PsO-Ped (NCT06979453)
- Testing
- Deucravacitinib
- Where
- 133 sites in United States, Argentina and 14 more
- Volunteers
- 366 people
- Sponsor
- Bristol-Myers Squibb
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Plaque Psoriasis
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 1 (NCT05223868)
- Testing
- JNJ-77242113
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 255 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
- Trial name
- Psoriasis (NCT06110676)
- Testing
- LZM012, Secukinumab
- Where
- China
- Volunteers
- 918 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Plaque Psoriasis, Skin Diseases
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
- Trial name
- CLEAR-PS (NCT03358290)
- Testing
- JTE-051
- Where
- 16 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Shionogi Inc.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis
This study is a prospective, single blinded, randomized, pilot study to compare the effectiveness and safety profile of oral versus subcutaneous route of administration of methotrexate in management of patients with moderate to…
- Trial name
- NCT03408756
- Testing
- methotrexate
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Severe Alopecia Areata
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.
- Trial name
- NCT06562894
- Testing
- SYHX1901
- Volunteers
- 156 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Psoriasis, Cardiovascular Diseases
The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis
Psoriasis vulgaris is no longer considered as a chronic inflammatory disease restricted to the skin. Evidence has accumulated in the past that psoriasis is a chronic inflammatory systemic disease.
- Conditions
- Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- CASTIP (NCT01088165)
- Testing
- Adalimumab treatment arm, Fumaric acid esters treatment group, Narrow band UVB radiation
- Where
- Austria
- Volunteers
- 66 people
- Sponsor
- Medical University of Vienna
Plaque Psoriasis
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06602219
- Testing
- LY4100511
- Where
- 58 sites in United States, Canada and 5 more
- Volunteers
- 222 people
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Plaque-type Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT01936688
- Testing
- MK-3222 200 mg, MK-3222 100 mg, Etanercept 50 mg
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis, Psoriasis
Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque…
- Trial name
- NCT02701205
- Testing
- etanercept, etanercept (half dose)
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Celgen Bio-Pharmaceutical Co.,Ltd